
浏览全部资源
扫码关注微信
400014 重庆,重庆医科大学附属儿童医院儿童生长发育与心理健康中心,国家儿童健康与疾病临床医学研究中心,儿童发育疾病研究教育部重点实验室,儿童神经发育与认知障碍重庆市重点实验室
[陈立,E-mail: chenli@cqmu.edu.cn CHEN Li, E-mail: chenli@cqmu.edu.cn
收稿:2024-04-11,
修回:2024-05-20,
纸质出版:2024-11-15
移动端阅览
杨靖媛, 李小莉, 吴春燕, 等. ADAM10抑制剂对孤独症样行为大鼠突触结构和血脑屏障通透性的影响[J]. 陆军军医大学学报, 2024,46(21):2457-2466.
Jingyuan YANG, Xiaoli LI, Chunyan WU, et al. Effects of ADAM10 inhibitor on synaptic structure and blood-brain barrier permeability in rats with autism-like behavior[J]. Journal of Army Medical University, 2024, 46(21): 2457-2466.
杨靖媛, 李小莉, 吴春燕, 等. ADAM10抑制剂对孤独症样行为大鼠突触结构和血脑屏障通透性的影响[J]. 陆军军医大学学报, 2024,46(21):2457-2466. DOI: 10.16016/j.2097-0927.202404037.
Jingyuan YANG, Xiaoli LI, Chunyan WU, et al. Effects of ADAM10 inhibitor on synaptic structure and blood-brain barrier permeability in rats with autism-like behavior[J]. Journal of Army Medical University, 2024, 46(21): 2457-2466. DOI: 10.16016/j.2097-0927.202404037.
目的
2
探讨解聚素金属蛋白酶10(a disintegrin and metalloprotease domain 10,ADAM10)抑制剂对孤独症样行为大鼠突触结构和血脑屏障(blood-brain barrier
BBB)通透性的影响。
方法
2
按照随机数字表法将50只孕期丙戊酸(valproic acid,VPA)诱导的子代雄性孤独症样行为大鼠分为2组(
n
=25):丙戊酸组(VPA组)、ADAM10抑制剂TAT-Pro-ADAM10(709-729)治疗组(TAT-Pro组),另取25只孕期生理盐水诱导的子代雄性大鼠作为对照组(CON组)。TAT-Pro组在生后第20天腹腔注射TAT-Pro-ADAM10(709-729) (3 nmol/g),CON组和VPA组给予等体积的生理盐水。记录造模期间各组子代大鼠体质量及尾长变化。Western blot检测给药24 h后子代大鼠海马组织中的ADAM10、血管内皮钙黏蛋白(vascular endothelial cadherin
VE-Cad)、咬合蛋白(Occludin)、带状闭合蛋白-1(zonula occludens-1
ZO-1)及突触后致密物-95(post-synaptic density
PSD95)、突触素(synaptophysin
SYN)的蛋白表达量。免疫荧光进一步验证ZO-1的蛋白表达。生后24 d进行旷场、梳毛、三箱社交及水迷宫行为学检测。高尔基染色检测生后28 d子代大鼠海马组织中树突棘密度。
结果
2
相较于VPA组,TAT-Pro组大鼠体质量及尾长无显著改变,但重复刻板行为、社交能力及学习记忆功能均显著改善(
P
<0.05),海马组织中ADAM10及PSD95蛋白表达水平显著降低(
P
<0.05),VE-Cad、Occludin蛋白表达水平均显著升高(
P
<0.05),且树突棘的密度显著降低(
P
<0.05)
未成熟的树突棘也减少。
结论
2
突触发育关键期,抑制ADAM10过表达可减轻VPA诱导的孤独症样行为大鼠的学习记忆功能,且对孤独症样行为大鼠的异常突触结构及BBB通透性有一定的修复作用。
Objective
2
To investigate the effects of a disintegrin and metalloprotease domain 10 (ADAM10) inhibitor on synaptic structure and blood-brain barrier (BBB) permeability in rats with autism-like behavior.
Methods
2
A total of 50 male offspring rats with prenatal exposure to valproic acid (VPA) to induce autism-like behavior were randomly divided into VPA group and ADAM10 inhibitor
TAT-Pro-ADAM10 (709-729) group (TAT-Pro group)
with 25 rats in each group. And another 25 offspring male rats induced by normal saline during pregnancy served as control group (CON group). The TAT-Pro group was given intraperitoneal injection on postnatal day 20 with 3 nmol/g TAT-Pro-ADAM10 (709-729)
and equal volumes of normal saline were given to the CON and VPA groups. The changes of body mass and tail length of offspring rats were measured and recorded during modeling. Western blotting was performed to detect the protein levels of ADAM10
vascular endothelial cadherin (VE-Cad)
Occludin
zonula occludens-1 (ZO-1)
post-synaptic density protein-95 (PSD95)
and synaptophysin (SYN) in the hippocampal tissue of the offspring rats in 24 h after administration. The expression of ZO-1 protein was further verified by immunofluorescence assay. Behavioral tests were conducted from postnatal day 24
including open field
grooming
three-chamber social interaction
and water maze tests. The density of dendritic spines in hippocampal tissue in the offspring rats on postnatal day 28 was detected by Golgi staining.
Results
2
Compared with the VPA group
the TAT-Pro group showed no significant changes in body weight and tail length
but significantly improved repetitive stereotyped behaviors
social skills and learning memory ability (
P
<
0.05)
reduced protein levels of ADAM10 and PSD95 in hippocampal tissues (
P
<
0.05)
and elevated levels of VE-cad and Occludin (
P
<
0.05). The density of dendritic spines was significantly reduced (
P
<
0.05)
and the number of immature dendritic spines also decreased in the TAT-Pro group than the VPA group.
Conclusion
2
Inhibition of ADAM10 overexpression during the critical period of synaptic development can alleviate learning and memory dysfunctions in VPA-induced rats with autism-like behavior
and has a certain restorative effect on abnormal synaptic structures and blood-brain barrier permeability.
LORD C, ELSABBAGH M, BAIRD G, et al . Autism spectrum disorder[J ] . Lancet, 2018 , 392(10146): 508-520. DOI: 10.1016/S0140-6736(18)31129-2.
GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Psychiatry, 2022, 9(2): 137-150. DOI: 10.1016/S2215-0366(21)00395-3.
MAENNER M J, WARREN Z, WILLIAMS A R, et al . Prevalence and characteristics of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2020[J ] . MMWR Surveill Summ, 2023, 72(2): 1-14. DOI: 10.15585/mmwr.ss7202a1.
LORD C, CHARMAN T, HAVDAHL A, et al . The Lancet Commission on the future of care and clinical research in autism[J ] . Lancet, 2022, 399(10321): 271-334. DOI: 10.1016/S0140-6736(21)01541-5.
戴旭芳, 秦利燕, 连继勤. 白藜芦醇对孤独症大鼠病症行为的改善作用[J]. 第三军医大学学报, 2017, 39(13): 1360-1365. DOI: 10.16016/j.1000-5404.201703153.
DAI X F, QIN L Y, LIAN J Q. Resveratrol improves autistic behaviors in rat model[J]. J Third Mil Med Univ, 2017, 39(13): 1360-1365. DOI: 10.16016/j.1000-5404.201703153.
LI X L, ZHOU P, LI Q, et al . Regressive autism spectrum disorder: high levels of total secreted amyloid precursor protein and secreted amyloid precursor protein-α in plasma[J ] . Front Psychiatry, 2022, 13: 809543. DOI: 10.3389/fpsyt.2022.809543.
NAU H, HAUCK R S, EHLERS K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms[J]. Pharmacol Toxicol, 1991, 69(5): 310-321. DOI: 10.1111/j.1600-0773.1991.tb01303.x.
RASALAM A D, HAILEY H, WILLIAMS J H, et al . Characteristics of fetal anticonvulsant syndrome associated autistic disorder[J ] . Dev Med Child Neurol, 2005, 47(8): 551-555. DOI: 10.1017/s0012162205001076.
KOREN G, NAVA-OCAMPO A A, MORETTI M E, et al . Major malformations with valproic acid[J ] . Can Fam Physician, 2006, 52(4): 441-442, 444, 447.
SMITH V, BROWN N. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism[J]. Arch Dis Child Educ Pract Ed, 2014, 99(5): 198. DOI: 10.1136/archdischild-2013-305636.
NICOLINI C, FAHNESTOCK M. The valproic acid-induced rodent model of autism[J]. Exp Neurol, 2018, 299: 217-227. DOI: 10.1016/j.expneurol.2017.04.017.
SHARON G, SAMPSON T R, GESCHWIND D H, et al . The central nervous system and the gut microbiome[J ] . Cell, 2016, 167(4): 915-932. DOI: 10.1016/j.cell.2016.10.027.
MARTIN M, VERMEIREN S, BOSTAILLE N, et al . Engineered Wnt ligands enable blood-brain barrier repair in neurological disorders[J ] . Science, 2022, 375(6582): eabm4459. DOI: 10.1126/science.abm4459.
FIORENTINO M, SAPONE A, SENGER S, et al . Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders[J ] . Mol Autism, 2016, 7: 49. DOI: 10.1186/s13229-016-0110-z.
ZHENG Y P, VERHOEFF T A, PEREZ PARDO P, et al . The gut-brain axis in autism spectrum disorder: a focus on the metalloproteases ADAM10 and ADAM17[J ] . Int J Mol Sci, 2020, 22(1): 118. DOI: 10.3390/ijms22010118.
柴伟娜, 程崇杰, 蒋理, 等. 膜粘连蛋白Ⅱ通过保护血脑屏障促进小鼠颅脑创伤后早期神经功能的恢复[J]. 第三军医大学学报, 2017, 39(18): 1808-1815. DOI: 10.16016/j.1000-5404.201703101.
CHAI W N, CHENG C J, JIANG L, et al . Recombinant annexin A2 improves early neurological function through blood-brain barrier protection in mice after controlled cortical impact[J ] . J Third Mil Med Univ, 2017, 39(18): 1808-1815. DOI: 10.16016/j.1000-5404.201703101.
SCHULZ B, PRUESSMEYER J, MARETZKY T, et al . ADAM10 regulates endothelial permeability and T-Cell transmigration by proteolysis of vascular endothelial cadherin[J ] . Circ Res, 2008, 102(10): 1192-1201. DOI: 10.1161/CIRCRESAHA.107.169805.
VEZZOLI E, CARON I, TALPO F, et al . Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease[J ] . J Clin Invest, 2019, 129(6): 2390-2403. DOI: 10.1172/JCI120616.
NAKAMURA M, LI Y H, CHOI B R, et al . GDE2-RECK controls ADAM10 α-secretase-mediated cleavage of amyloid precursor protein[J ] . Sci Transl Med, 2021, 13(585): eabe6178. DOI: 10.1126/scitranslmed.abe6178.
ZENG J Y, CHEN L, WANG Z, et al . Marginal vitamin A deficiency facilitates Alzheimer's pathogenesis[J ] . Acta Neuropathol, 2017, 133(6): 967-982. DOI: 10.1007/s00401-017-1669-y.
SAFTIG P, LICHTENTHALER S F. The alpha secretase ADAM10: a metalloprotease with multiple functions in the brain[J]. Prog Neurobiol, 2015, 135: 1-20. DOI: 10.1016/j.pneurobio.2015.10.003.
PROX J, BERNREUTHER C, ALTMEPPEN H, et al . Postnatal disruption of the disintegrin/metalloproteinase ADAM10 in brain causes epileptic seizures, learning deficits, altered spine morphology, and defective synaptic functions[J ] . J Neurosci, 2013, 33(32): 12915-12928, 12928a. DOI: 10.1523/JNEUROSCI.5910-12.2013.
PASCIUTO E, AHMED T, WAHLE T, et al . Dysregulated ADAM10-mediated processing of APP during a critical time window leads to synaptic deficits in fragile X syndrome[J ] . Neuron, 2015, 87(2): 382-398. DOI: 10.1016/j.neuron.2015.06.032.
ZHANG Q, XING M G, BAO Z K, et al . Contactin-associated protein-like 2 (CNTNAP2) mutations impair the essential α-secretase cleavages, leading to autism-like phenotypes[J ] . Signal Transduct Target Ther, 2024, 9(1): 51. DOI: 10.1038/s41392-024-01768-6.
LUO L J, LI T Y, WU Q H, et al . Retinoic acid administration normalizes aberrant microglial activation via regulating TREM2 transcription in the PFC of valproic acid induced autism rat[J ] . Neurosci Lett, 2023, 803: 137193. DOI: 10.1016/j.neulet.2023.137193.
EPIS R, MARCELLO E, GARDONI F, et al . Blocking ADAM10 synaptic trafficking generates a model of sporadic Alzheimer's disease[J ] . Brain, 2010, 133(11): 3323-3335. DOI: 10.1093/brain/awq217.
BAUMAN M L, KEMPER T L. Neuroanatomic observations of the brain in autism: a review and future directions[J]. Int J Dev Neurosci, 2005, 23(2/3): 183-187. DOI: 10.1016/j.ijdevneu.2004.09.006.
APPEL D, HUMMEL R, WEIDEMEIER M, et al . Pharmacologic inhibition of ADAM10 attenuates brain tissue loss, axonal injury and pro-inflammatory gene expression following traumatic brain injury in mice[J ] . Front Cell Dev Biol, 2021, 9: 661462. DOI: 10.3389/fcell.2021.661462.
MEHRA S, AHSAN A U, SHARMA M, et al . Gestational fisetin exerts neuroprotection by regulating mitochondria-directed canonical Wnt signaling, BBB integrity, and apoptosis in prenatal VPA-induced rodent model of autism[J ] . Mol Neurobiol, 2024, 61(7): 4001-4020. DOI: 10.1007/s12035-023-03826-6.
ZOHNY S M, HABIB M Z, MOHAMAD M I, et al . Memantine/aripiprazole combination alleviates cognitive dysfunction in valproic acid rat model of autism: hippocampal CREB/BDNF signaling and glutamate homeostasis[J ] . Neurotherapeutics, 2023, 20(2): 464-483. DOI: 10.1007/s13311-023-01360-w.
ZHANG Y H, YUAN X S, WANG Z P, et al . The canonical Wnt signaling pathway in autism[J ] . CNS Neurol Disord Drug Targets, 2014, 13(5): 765-770. DOI: 10.2174/1871527312666131223114149.
LIEBNER S, DIJKHUIZEN R M, REISS Y, et al . Functional morphology of the blood-brain barrier in health and disease[J ] . Acta Neuropathol, 2018, 135(3): 311-336. DOI: 10.1007/s00401-018-1815-1.
MA S R, ZUO Y. Synaptic modifications in learning and memory—A dendritic spine story[J]. Semin Cell Dev Biol, 2022, 125: 84-90. DOI: 10.1016/j.semcdb.2021.05.015.
MARTÍNEZ-CERDEÑO V. Dendrite and spine modifications in autism and related neurodevelopmental disorders in patients and animal models[J]. Dev Neurobiol, 2017, 77(4): 393-404. DOI: 10.1002/dneu.22417.
LO L H Y, LAIK O. Dysregulation of protein synthesis and dendritic spine morphogenesis in ASD: studies in human pluripotent stem cells[J]. Mol Autism, 2020, 11(1): 40. DOI: 10.1186/s13229-020-00349-y.
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621